Lataa...
Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers
Mithramycin A (1) was identified as the top potential inhibitor of the aberrant ETS transcription factor EWS-FLI1, which causes Ewing sarcoma. Unfortunately, 1 has a narrow therapeutic window, compelling us to seek less toxic and more selective analogues. Here, we used MTMSA (2) to generate analogue...
Tallennettuna:
| Julkaisussa: | J Med Chem |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6888919/ https://ncbi.nlm.nih.gov/pubmed/30114371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b01107 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|